A5107791462- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- RNA modifications and cancer
- Cancer-related molecular mechanisms research
- Ferroptosis and cancer prognosis
- Lung Cancer Research Studies
- Immunotherapy and Immune Responses
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- Immune Cell Function and Interaction
- Genomics, phytochemicals, and oxidative stress
- Cancer Cells and Metastasis
- Peptidase Inhibition and Analysis
- Esophageal and GI Pathology
- Glycosylation and Glycoproteins Research
- Receptor Mechanisms and Signaling
- IL-33, ST2, and ILC Pathways
- NF-κB Signaling Pathways
- Cancer, Hypoxia, and Metabolism
- RNA Research and Splicing
- Pleural and Pulmonary Diseases
- Circular RNAs in diseases
- Inflammasome and immune disorders
Soochow University
2016-2025
First Affiliated Hospital of Soochow University
2016-2025
South China Sea Institute Of Oceanology
2024-2025
Institute of Oceanology
2024-2025
University of Chinese Academy of Sciences
2024-2025
Second Affiliated Hospital of Soochow University
2025
Guilin Medical University
2025
First Affiliated Hospital of Henan University of Traditional Chinese Medicine
2020-2025
Chinese Academy of Sciences
2024
The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital)
2024
PURPOSE ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079 ), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients with epidermal growth factor receptor ( EGFR) mutation-positive resected stage II-IIIA (N1-N2) non–small-cell lung cancer (NSCLC). Here, we report the final overall (OS) results. METHODS From September 2011 to April 2014, 222 from 27 sites were...
Importance Adjuvant and neoadjuvant immunotherapy have improved clinical outcomes for patients with early-stage non–small cell lung cancer (NSCLC). However, the optimal combination of checkpoint inhibition chemotherapy remains unknown. Objective To determine whether toripalimab in platinum-based will improve event-free survival major pathological response stage II or III resectable NSCLC compared alone. Design, Setting, Participants This randomized trial enrolled (without EGFR ALK...
BackgroundThe comparison between relatively intact nanoscale extracellular vesicle-derived DNA (nEV-DNA) and fragmented circulating cell-free (cfDNA) in mutation detection among patients with non-small-cell lung cancer (NSCLC) has not been carried out yet, thus deserves investigation.Patients methodsBoth nEV-DNA cfDNA was obtained from 377 NSCLC known EGFR status 69 controls. The respective EGFRE19del/T790M/L858R interrogated amplification-refractory-mutation-system-based PCR assays...
Several targeted immunotherapies have recently showed significant advances in treatment of non-small cell lung cancer (NSCLC), including antibodies and inhibitors targeting programmed death-1 (PD-1) its ligand (PD-L1).Tumor tissue samples were prospectively collected from 183 patients with NSCLC adenocarcinoma (ADC) squamous carcinoma (SQCC). PD-L1 expression level was measured by immunohistochemistry assay tumor mutational burden (TMB) status assessed next generation sequencing....
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. randomized, open-label, phase II EVAN study investigated efficacy (disease-free survival [DFS] and 5-year overall...
Abstract Background Lung cancer has high morbidity and mortality across the globe, lung adenocarcinoma (LUAD) is most common histologic subtype. Disordered lipid metabolism related to development of cancer. Analysis lipid-related transcriptome helps shed light on diagnosis prognostic biomarkers LUAD. Methods In this study, expression analysis 1045 metabolism-related genes was performed between LUAD tumors normal tissues derived from Cancer Genome Atlas Adenocarcinoma (TCGA-LUAD) cohort. The...
During the coronavirus disease (COVID-19) epidemic, there have been concerns about impact of vaccines on people's fertility, including fertility those who are currently preparing for pregnancy and might become pregnant in future. However, is still a lack research effect COVID-19 vaccine male it not surprising that couples donors regarding vaccination. In this study, retrospective cohort study was conducted to examine semen quality before after receipt inactivated vaccine. There were no...
Accumulating evidences demonstrate that a population of suppressive cells known as myeloid-derived suppressor (MDSCs) is key immune modulators which suppress antitumor immunity. In this study, we found the level circulating CD14(+)HLA-DR(-/low) in patients was significantly higher than healthy donors and correlated with tumor burden, lymph node metastasis, tumor, node, metastasis (TNM) clinical stage. More importantly, for first time find biological indicator poor prognosis through analysis...
Uvarialeptones A-C were isolated via phytochemical investigation into the Uvaria leptopoda. A & C specifically demonstrate SNU-1 human gastric cancer cells cytotoxicity comparable to cisplatin. Other potential biological activities of leptopoda derivatives remain be further investigated. Given recorded medicinal uses genus, such may prove fruitful. Viable synthesis schemes for these compounds are crucial investigations. The following paper retrosynthetic analysis both uvarialeptone and...
Background Despite undergoing surgery and chemoradiotherapy, patients with first primary lung cancer (FPLC) remain at risk for second (SPLC), which is associated a poor prognosis. The effects of FPLC chemoradiotherapy on SPLC prognosis its sensitivity to re-chemoradiotherapy have not been adequately investigated. Methods This cohort study analyzed data from 23,827 who underwent during 1973–2021, drawn the Surveillance, Epidemiology, End Results database. Among these, 5,302 developed within 5...
<title>Abstract</title> Background: Nasopharyngeal carcinoma (NPC) is common in Southeast Asia, with most patients diagnosed locally advanced disease. Radiotherapy alone often ineffective, so platinum-based chemotherapy combined for better outcomes. However, response and side effects vary among patients. Genetic markers, particularly human leukocyte antigen (HLA) killer-cell immunoglobulin-like receptors (KIR), have been implicated modulating sensitivity toxicity. Identifying these markers...
Postoperative pulmonary infections (POPIs) occur in approximately 13–38% of patients who undergo surgery for esophageal cancer, negatively impacting patient outcomes and prolonging hospital stays. This study aims to develop a novel clinical prediction model identify at risk POPIs early, thereby enabling timely intervention by clinicians. included 910 from two hospitals. Of these, 795 one were randomly assigned the training cohort (n = 556) validation 239) 7:3 ratio. The external test...
Long non-coding RNAs (lncRNAs) have been shown to play important roles in human cancers, including esophageal squamous cell carcinoma (ESCC). In the current study, we identified CCAT2 as a relevant lncRNA and investigated its role progression of ESCC. RT-qPCR was adopted detect expression collected clinical samples, ESCC lines, normal line. We tested correlation between prognosis or immunoblotting factors tissues cells. Cell proliferation, apoptosis, migration, invasion were examined by...